Barrera-Cruz A, Díaz-Ramos RD, Viniegra-Osorio A, Grajales-Muñiz C, Dávila-Torres J

Language: Spanish
References: 27
Page: 102-119
PDF size: 224.07 Kb.

ABSTRACT

Chikungunya fever is an emerging disease caused by an alphavirus belonging to the Togaviridae family, transmitted by the bite of Aedes genus species: Aedesaegypti and Aedesalbopictus. In 2013, PAHO/ WHO received confi rmation of the fi rst cases of indigenous transmission of chikungunya in the Americas. This disease may be acute, subacute and chronic, affecting all age groups. Following an incubation period from three to seven days, the patient usually begins with a high fever (greater than 39 ^°C), arthralgia, back pain, headache, nausea, vomiting, arthritis, rash, and conjunctivitis (acute phase: 3-10 days). Most patients recover fully, but in some cases, joint involvement may persist chronically and cause discapacity and affect life quality. Serious complications are rare, however, attention must be focused on vulnerable populations (the elderly, children and pregnant women). So far, there is no specifi c antiviral treatment or effective vaccine, so it is giving priority symptomatic and supportive treatment for the acute phase and make an early diagnosis of atypical and severe forms, and to implement effective prevention and control measures. Given the eco-epidemiological conditions and distribution of vectors in the region of the Americas, the spread of the virus to other countries is likely, so that health professionals should be aware of and identify risk factors and major clinical manifestations, allow timely prevention and safe and effective treatment of this disease.

REFERENCES

1. OPS. Chikunguña. http://www.paho.org/hq/index. php?option=com_topics&view=article&id=343&Ite mid=40931&lang=es

2. OPS/CDC. La preparación y la respuesta frente al virus Chikunguña en las Américas. Washington, D.C.: LA OPS, 2011. http:/www.paho.org/hq/ index.php?option=com_docman&task=doc_ download&gid=16984& Itemid=&lang=en

3. CDC. http://www.cdc.gov/chikunguña/

4. Guía de manejo clínico para la infección por el virus chikunguña (CHIKV). Santo Domingo, República Dominicana Mayo 2014.

5. Organización Mundial de la Salud, Ofi cina Regional de Ofi cina Regional de Asia Sudoriental. Directrices para el Manejo Clínico de la fi ebre de Chikunguña. Nueva Delhi, 2008. http:/www.searo.who.int/entity/ emerging_diseases/documents/SEA_CD_180/en/ index .html

6. OMS Chikunguña. Nota descriptiva N°327 Marzo de 2014. Disponible en: http://www.who.int/ mediacentre/factsheets/fs327/es/

7. WHO. Guidelines on Clinical Management of Chikunguña Fever; 2008. http://www.searo.who. int/LinkFiles/Publication_guidelines_on_cli_mgmt_ chikunguña _fvr-(cd-180).pdf. Accessed 09 October 2014

8. Secretaria de Salud. Dirección General de Epidemiología. Lineamientos estandarizados para la vigilancia epidemiológica y diagnóstico por laboratorio para fi ebre chikunguña. Julio 2014

9. NORMA Ofi cial Mexicana NOM-017-SSA2-2012, Para la vigilancia epidemiológica.

10. Mohan A. Chikunguña fever: clinical manifestations & management. Indian J Med Res 2006;124(5):471-474.

11. Pialoux G, Gauzere BA, Jaureguiberry S, Strobel M. Chikunguña, an epidemic arbovirosis. Lancet Infect Dis 2007;7(5):319-327.

12. Comité Nacional para la Vigilancia Epidemiológica. CONAVE. Situación Epidemiológica de Virus Chikunguña en América. Aviso Epidemiológico CoNaVE /3/ 2014 / CHIKUNGUÑA 12 de junio de 2014.

13. Horcada ML, Díaz-Calderón C, Garrido L. Chikunguña fever. Rheumatic manifestations of an emerging disease in Europe. Reumatol Clin 2014 Sep 2. pii: S1699-258X(14)00158-2. doi: 10.1016/j. reuma.2014.07.005. [Epub ahead of print]

14. Caglioti C, Lalle E, Castilletti C, Carletti F, Capobianchi MR, Bordi L. Chikunyunga virus infecction: An overview. New Microbiol. 2013;36:211–227.

15. Chopra A, Saluja M, Venugopalan A. Effectiveness of chloroquine and infl ammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikunguña virus infection. Arthritis Rheumatol 2014;66:319–326.

16. Staikowsky F, Talarmi P, Grivard P, Souabschuffenecker I, Le Roux K, Lecuit M, et al. Prospective study of Chikingunya virus acute infection in de Island of la Reunion during the 2005- 2006 outbreak. PLoS One 2009;28:4.

17. Morrison TE. Reemergence of Chikunguña Virus. J Virol 2014;88(20):11644-11647.

18. Van Bortel W, Dorleans F, Rosine J, Blateau A, Rousset D, Matheus S, et al. Chikunguña outbreak in the Caribbean region, December 2013 to March 2014, and the signifi cance for Europe.Euro Surveill 2014;19(13). pii: 20759.

19. Bettadapura J, Herrero LJ, Taylor A, Mahalingam S. Approaches to the treatment of disease induced by chikunguña virus. Indian J Med Res 2013;138(5):762-765.

20. Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de Lamballerie X. Chikunguña fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res 2013;99(3):345-370.

21. Staples JE, Fischer M. Chikunguña virus in the Americas--what a vectorborne pathogen can do. N Engl J Med 2014;371(10):887-889.

22. Tomasello D, Schlagenhauf P. Chikunguña and dengue autochthonous cases in Europe, 2007-2012. Travel Med Infect Dis 2013;11(5):274-284.

23. Bajak A. US assesses virus of the Caribbean. Nature 2014;512(7513):124-125.

24. Requena-Méndez A, Garcia C, Aldasoro E, Vicente JA, Martínez MJ, Pérez-Molina JA, wt al. Cases of chikunguña virus infection in travellers returning to Spain from Haiti or Dominican Republic, April-June 2014.Euro Surveill 2014;19(28):20853.

25. Ramful D, Carbonnier M, Pasquet M, et al. Motherto- child transmission of chikunguña virus infection.

26. Pediatr Infect Dis J 2007;26(9):811-815.

27. Secretaria de Salud. Manual de Procedimientos Estandarizados para la Vigilancia Epidemiológica de la Enfermedades transmitidas por Vectores, 2012. Disponible en : http://www.epidemiologia.salud.gob. mx/doctos/infoepid/vig_epid_manuales/32_2012_ Manual_ETV_preliminar.pdf